ObsEva SA (OBSV) Stock Rating Reaffirmed by HC Wainwright
ObsEva SA (NASDAQ:OBSV)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday. They currently have a $27.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 289.61% from the company’s previous close.
Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of ObsEva SA from a “sell” rating to a “hold” rating in a research report on Friday. Leerink Swann restated an “outperform” rating and issued a $18.00 price target on shares of ObsEva SA in a research report on Wednesday, August 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $23.25.
ObsEva SA (NASDAQ OBSV) traded down 3.21% during mid-day trading on Friday, reaching $6.93. 20,123 shares of the company were exchanged. ObsEva SA has a one year low of $5.00 and a one year high of $14.69. The stock’s market capitalization is $197.48 million. The stock has a 50 day moving average of $7.56 and a 200-day moving average of $8.55.
ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.13. During the same period in the prior year, the company posted ($0.30) EPS. On average, equities analysts expect that ObsEva SA will post ($2.32) earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Baker Avenue Asset Management LP bought a new position in ObsEva SA during the first quarter valued at $104,000. Paloma Partners Management Co bought a new position in ObsEva SA during the first quarter valued at $131,000. Iguana Healthcare Management LLC bought a new position in ObsEva SA during the first quarter valued at $260,000. Spark Investment Management LLC bought a new position in ObsEva SA during the first quarter valued at $518,000. Finally, Nexthera Capital LP bought a new position in ObsEva SA during the first quarter valued at $521,000. Institutional investors and hedge funds own 48.46% of the company’s stock.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.